A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)
Latest Information Update: 07 Mar 2025
At a glance
- Drugs EO 2002 (Primary)
- Indications Corneal disorders
- Focus Adverse reactions; Proof of concept
- Acronyms EMME-01
- Sponsors Emmecell
Most Recent Events
- 03 Mar 2025 Status changed from active, no longer recruiting to completed.
- 18 Nov 2024 Results presented in the Emmecell media release.
- 08 Oct 2024 According to Emmecell media release, Emmecell Completes last patient last visit in its phase 1 extension study EMME-001 and additional detailed topline results are expected to be reported in the next month for all subjects treated across three doses of EO2002.